Dan Ferry
Host
Replay available
Rain Enhancement Technologies Holdco, Inc. (RAIN) Q1 2023 Earnings Call
Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) Q1 2023 earnings conference call, held 2023-05-11. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Avinash Vellanki
Chief Executive Officer
Dr. Robert Doble
Chief Scientific Officer
Dr. Richard Bryce
Chief Medical Officer
Nelson Caviton
SVP of Finance
Michael Schmidt
Analyst, Guggenheim
Joe Catanzaro
Analyst, Piper Sandler
Sumit Roy
Analyst, Jones Trading
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Rain Enhancement Technologies Holdco, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.049 -- 00:00:03.171 Greetings and welcome to the RAINN Oncology, Inc. 00:00:03.171 -- 00:00:05.393 First Quarter 2023 Earnings 00:00:05.393 -- 00:00:10.876 Call. At this time, all participants are in a listen-only mode. 00:00:10.876 -- 00:00:15.399 A brief question and answer session will follow the formal presentation. 00:00:15.399 -- 00:00:19.862 If anyone should require operator assistance during the conference, please press star 00:00:19.862 -- 00:00:22.564 then zero on your telephone keypad. 00:00:22.564 -- 00:00:25.966 As a reminder, this conference is being recorded. 00:00:25.966 -- 00:00:29.315 It is now my pleasure to introduce your host, Dan Ferry. 00:00:29.315 -- 00:00:32.496 Thank you. Dan, you might begin. 00:00:32.878 -- 00:00:35.520 Thank you, operator, and good afternoon, everyone. 00:00:35.520 -- 00:00:41.004 With me today on the phone are Avinash Vellanki, Chief Executive Officer of RAIN Oncology, 00:00:41.004 -- 00:00:45.267 Dr. Robert Doble, Chief Scientific Officer, Dr. 00:00:45.267 -- 00:00:50.511 Richard Bryce, Chief Medical Officer, and Nelson Caviton, SVP 00:00:50.511 -- 00:00:52.651 of Finance. 00:00:52.713 -- 00:00:57.771 During today's call, Avinash will provide an update on the broader strategic vision 00:00:57.771 -- 00:01:03.036 for the Milidemetan franchise. Bob will review the biology and rationale of P53 00:01:03.036 -- 00:01:04.598 reactivation 00:01:04.598 -- 00:01:10.043 and discuss possibilities for future clinical development of Milidemetan based on non-clinical 00:01:10.043 -- 00:01:11.925 research. 00:01:11.925 -- 00:01:16.389 Richard will provide an update on RAIN's clinical strategy, and Nelson will review the 00:01:16.389 -- 00:01:18.314 financials. 00:01:18.314 -- 00:01:22.717 Before we begin, I would like ...